Bio-Rad Laboratories (BIO) AI Stock Analysis

• Market Cap: $8.65B
• Dividend Yield: N/A
• Average Volume (3M): 227.37K
• Price to Earnings (P/E): 27.2
• Beta (1Y): 0.75
• Revenue Growth: -0.33%
• EPS Growth: N/A
• Country: US
• Employees: 7,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 2.26
• Shares Outstanding: 21,992,308
• 10 Day Avg. Volume: 256,468
• 30 Day Avg. Volume: 227,367
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: 2.58
• Enterprise Value/Gross Profit: 4.89
• Enterprise Value/Ebitda: 9.62
• 1Y Price Target: $342.33
• Price Target Upside: 3.60% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 68 Neutral
• Price Target: $360.00 ▲(8.95% Upside)

Bio-Rad Laboratories' stock score reflects a stable financial foundation with low leverage and improving profitability. The technical indicators show bullish momentum, but valuation concerns arise due to a high P/E ratio and lack of dividend yield. Earnings call insights reveal resilience in certain areas but also highlight ongoing challenges, leading to a cautiously optimistic outlook.

Positive Factors

Strong Balance Sheet

Bio-Rad's low leverage provides financial stability and flexibility, allowing the company to invest in growth opportunities without significant financial risk.

Process Chromatography Growth

Strong growth in process chromatography indicates robust demand and strengthens Bio-Rad's market position in this segment, supporting long-term revenue potential.

Cash Flow Generation

Improved cash flow generation enhances Bio-Rad's ability to fund operations, invest in R&D, and pursue strategic initiatives, supporting sustainable growth.

Negative Factors

Life Science Segment Weakness

The decline in the Life Science segment reflects challenges in key markets, potentially impacting Bio-Rad's revenue growth and market competitiveness.

Gross Margin Decline

Decreasing gross margins due to higher costs may pressure profitability, necessitating cost management to maintain financial health.

Challenges in China

Reduced sales in China due to reimbursement issues could hinder growth in a key market, affecting overall revenue and strategic expansion efforts.

Bio-Rad Laboratories Business Overview & Revenue Model

Company Description

Bio-Rad Laboratories, Inc. is a global leader in the life sciences and clinical diagnostics sectors, providing innovative products and solutions that enhance research and healthcare. Founded in 1952, the company operates in two primary segments: Life Science and Clinical Diagnostics. Bio-Rad's core offerings include a wide range of reagents, instruments, and software used in laboratories for applications such as drug discovery, genetic research, and clinical diagnostics, enabling scientists and healthcare professionals to achieve accurate results efficiently.

How the Company Makes Money

Bio-Rad generates revenue through the sale of a diverse portfolio of products primarily in the life sciences and clinical diagnostics markets. The Life Science segment contributes significantly to revenue through the sale of reagents, instruments, and consumables utilized in research and drug development. Key revenue streams include products for protein purification, gene expression analysis, and cellular biology. In the Clinical Diagnostics segment, the company earns revenue from diagnostic tests and assays that aid in disease detection and management, including immunology, blood typing, and infectious disease testing. Additionally, Bio-Rad has established partnerships with various healthcare organizations and research institutions, which help expand its market reach and drive sales. The company also benefits from recurring revenue through consumables and maintenance contracts tied to its instruments, creating a stable income stream.

Bio-Rad Laboratories Financial Statement Overview

Summary

Bio-Rad Laboratories shows signs of recovery with improvements in profitability and cash flow generation. The company maintains a strong balance sheet with low leverage, providing a stable financial foundation. However, the company needs to focus on sustaining revenue growth and enhancing profitability to achieve industry-leading performance.

Income Statement

Bio-Rad Laboratories has shown a mixed performance in its income statement. The TTM (Trailing-Twelve-Months) data indicates a gross profit margin of 52.8%, which is healthy, but there is a significant decline in net profit margin to 12.5% from previous negative margins, indicating improvement but still below industry standards. Revenue growth has been inconsistent, with a recent positive trend of 51.6% in TTM, suggesting recovery. EBIT and EBITDA margins have improved to 19.5% and 26.9% respectively, showing better operational efficiency.

Balance Sheet

The balance sheet of Bio-Rad Laboratories reflects a stable financial position with a debt-to-equity ratio of 0.20, indicating low leverage and financial risk. The return on equity (ROE) has improved to 4.6% in TTM, recovering from negative values, but still needs enhancement. The equity ratio stands at a solid 69.8%, showcasing a strong equity base relative to total assets.

Cash Flow

Cash flow analysis reveals a positive trend with a free cash flow growth rate of 4.6% in TTM, indicating better cash generation. The operating cash flow to net income ratio is nearly 1, suggesting efficient conversion of income into cash. The free cash flow to net income ratio is 65.1%, reflecting a good level of cash flow relative to profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.55B	2.57B	2.67B	2.80B	2.92B	2.55B
Gross Profit	1.35B	1.38B	1.43B	1.57B	1.64B	1.44B
EBITDA	686.19M	-2.14B	-654.80M	-4.49B	5.59B	5.08B
Net Income	319.17M	-1.84B	-637.32M	-3.63B	4.25B	3.81B
Balance Sheet
Total Assets	10.21B	9.36B	12.30B	13.50B	17.80B	12.97B
Cash, Cash Equivalents and Short-Term Investments	1.37B	1.66B	1.61B	1.79B	869.92M	991.12M
Total Debt	1.41B	1.37B	1.41B	1.39B	223.38M	225.74M
Total Liabilities	3.09B	2.79B	3.56B	3.89B	4.11B	3.09B
Stockholders Equity	7.13B	6.57B	8.74B	9.62B	13.69B	9.88B
Cash Flow
Free Cash Flow	347.52M	266.20M	218.26M	80.29M	535.72M	476.41M
Operating Cash Flow	534.16M	455.20M	374.94M	194.45M	669.46M	584.97M
Investing Cash Flow	-198.68M	-160.20M	20.21M	-1.21B	-797.38M	-69.89M
Financing Cash Flow	-356.23M	-218.80M	-425.65M	973.58M	-55.43M	-523.04M

Bio-Rad Laboratories Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 330.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIO, the sentiment is Positive. The current price of 330.42 is above the 20-day moving average (MA) of 314.76, above the 50-day MA of 297.59, and above the 200-day MA of 271.67, indicating a bullish trend. The MACD of 11.50 indicates Negative momentum. The RSI at 55.84 is Neutral, neither overbought nor oversold. The STOCH value of 61.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BIO.

Bio-Rad Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	―	$117.66B	25.74	9.72%	3.02%	4.98%	22.08%
BSX	―	$148.62B	53.64	―	―	21.62%	54.80%
EW	―	$48.55B	56.45	15.71%	―	-5.23%	-39.83%
DXCM	―	$26.74B	47.73	22.83%	―	9.30%	-14.95%
BIO	―	$8.65B	27.23	4.59%	―	-0.33%	―
PHG	―	$26.43B	-33.81	―	3.25%	-0.76%	-55.03%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Bio-Rad Laboratories Corporate Events

Bio-Rad Laboratories Reports Stable Q3 2025 Results

Bio-Rad Laboratories, Inc. is a prominent player in the life science research and clinical diagnostics sectors, known for its innovative products that advance scientific research and healthcare diagnostics globally.

Bio-Rad Reports Q3 2025 Financial Results Amid Challenges

On October 29, 2025, Bio-Rad Laboratories reported its financial results for the third quarter ended September 30, 2025. Despite challenges in academic research and biotech funding, the company achieved a slight increase in revenue to $653.0 million, up 0.5% from the previous year. However, a change in the fair market value of its investment in Sartorius AG led to a significant net loss of $341.9 million. The company maintained its full-year 2025 financial outlook, expecting non-GAAP, currency-neutral revenue growth of 0 to 1.0 percent.

The most recent analyst rating on (BIO) stock is a Buy with a $366.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.

Bio-Rad Laboratories Mourns Loss of Co-Founder Alice Schwartz

On September 29, 2025, Bio-Rad Laboratories announced the passing of its co-founder and Director Emeritus, Alice N. Schwartz, on September 25, 2025, at the age of 99. Alice Schwartz, who co-founded the company in 1952, played a pivotal role in its growth and success, particularly in the development of Bio-Rad’s first test kit for thyroid function, which marked the company’s entry into clinical diagnostics. Her leadership and passion for scientific discovery have left a lasting legacy at Bio-Rad and in the broader scientific community.

The most recent analyst rating on (BIO) stock is a Hold with a $288.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.

Bio-Rad Hosts Webinar on Digital PCR Advancements

On August 26, 2025, Bio-Rad Laboratories hosted an informational webinar on its Droplet Digital PCR product portfolio, highlighting the technology’s precision and scalability. The event, led by company executives, aimed to showcase Bio-Rad’s leadership in digital PCR and its potential to drive future growth by transitioning customers from traditional PCR methods to its advanced digital solutions.

The most recent analyst rating on (BIO) stock is a Buy with a $336.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.

Bio-Rad Laboratories’ Earnings Call Highlights Growth and Challenges

Bio-Rad Laboratories’ recent earnings call painted a picture of solid execution and growth, particularly in the Life Sciences segment, despite facing challenges such as gross margin declines and increased expenses. The call highlighted a balanced outlook, with positive developments in key areas offsetting some market softness.

Bio-Rad Laboratories Reports Q2 2025 Financial Results

Bio-Rad Laboratories, Inc., based in Hercules, California, is a prominent player in the life sciences and clinical diagnostics sectors, known for its innovative products that advance scientific research and healthcare diagnostics globally.

Bio-Rad Reports Q2 2025 Financial Results

Bio-Rad Laboratories announced its financial results for the second quarter of 2025, reporting a 2.1% increase in total net sales compared to the same period in 2024, driven by higher sales in process chromatography products. The company completed the acquisition of Stilla Technologies, enhancing its Droplet Digital PCR offerings. Despite a slight decline in gross margin and income from operations, Bio-Rad recognized a significant net income due to changes in the fair market value of its investment in Sartorius AG. The company updated its full-year 2025 financial outlook, expecting non-GAAP, currency-neutral revenue growth of approximately 0 to 1.0 percent.

The most recent analyst rating on (BIO) stock is a Buy with a $400.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.